Editorial commentary: "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?

Nelson Lee; Michael G. Ison

doi:10.1093/cid/cis642

Editorial commentary: "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?

Nelson Lee^*, Michael G. Ison

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Comment/debate › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	1205-1208
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	55
Issue number	9
DOIs	https://doi.org/10.1093/cid/cis642
State	Published - Nov 1 2012

Funding

ceived grant support from F. Hoffmann–La Roche for principal investigator–initiated clinical influenza research, paid to the Chinese University of Hong Kong; an honorarium for consultancy work for GlaxoSmithKline; and conference support from Sanofi-Aventis Hong Kong, MSD (Asia) and Pfizer Hong Kong, paid to the Chinese University of Hong Kong. M. G. I. has received research support, paid to Northwestern University Feinberg School of Medicine, from BioCryst, Cellex, Genentech/Roche, and Glaxo-SmithKline. He is a paid member of a data and safety monitoring board for NexBio and has provided remunerated consultation to Abbott, Crucell, and Genentech/Roche; he has also provided unremunerated consultation to Adamas, Alios, BioCryst, Biota, Cellex, Clarassance, Glaxo-SmithKline, MediVector/Toyama, TheraClone, and Visterra.

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cis642

Cite this

@article{902a5ea876d24cf797dc18d948aba3bf,

title = "Editorial commentary: {"}Late{"} treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?",

author = "Nelson Lee and Ison, {Michael G.}",

note = "Funding Information: ceived grant support from F. Hoffmann–La Roche for principal investigator–initiated clinical influenza research, paid to the Chinese University of Hong Kong; an honorarium for consultancy work for GlaxoSmithKline; and conference support from Sanofi-Aventis Hong Kong, MSD (Asia) and Pfizer Hong Kong, paid to the Chinese University of Hong Kong. M. G. I. has received research support, paid to Northwestern University Feinberg School of Medicine, from BioCryst, Cellex, Genentech/Roche, and Glaxo-SmithKline. He is a paid member of a data and safety monitoring board for NexBio and has provided remunerated consultation to Abbott, Crucell, and Genentech/Roche; he has also provided unremunerated consultation to Adamas, Alios, BioCryst, Biota, Cellex, Clarassance, Glaxo-SmithKline, MediVector/Toyama, TheraClone, and Visterra.",

year = "2012",

month = nov,

day = "1",

doi = "10.1093/cid/cis642",

language = "English (US)",

volume = "55",

pages = "1205--1208",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Editorial commentary

T2 - "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?

AU - Lee, Nelson

AU - Ison, Michael G.

N1 - Funding Information: ceived grant support from F. Hoffmann–La Roche for principal investigator–initiated clinical influenza research, paid to the Chinese University of Hong Kong; an honorarium for consultancy work for GlaxoSmithKline; and conference support from Sanofi-Aventis Hong Kong, MSD (Asia) and Pfizer Hong Kong, paid to the Chinese University of Hong Kong. M. G. I. has received research support, paid to Northwestern University Feinberg School of Medicine, from BioCryst, Cellex, Genentech/Roche, and Glaxo-SmithKline. He is a paid member of a data and safety monitoring board for NexBio and has provided remunerated consultation to Abbott, Crucell, and Genentech/Roche; he has also provided unremunerated consultation to Adamas, Alios, BioCryst, Biota, Cellex, Clarassance, Glaxo-SmithKline, MediVector/Toyama, TheraClone, and Visterra.

PY - 2012/11/1

Y1 - 2012/11/1

UR - http://www.scopus.com/inward/record.url?scp=84867514129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867514129&partnerID=8YFLogxK

U2 - 10.1093/cid/cis642

DO - 10.1093/cid/cis642

M3 - Comment/debate

C2 - 22843780

AN - SCOPUS:84867514129

SN - 1058-4838

VL - 55

SP - 1205

EP - 1208

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Editorial commentary: "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: Better late than never?

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this